|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape for U.S. Patent 9,517,236
What Is the Scope and Core Claims of Patent 9,517,236?
U.S. Patent 9,517,236 covers a specific therapeutic compound, its formulation, and methods of use. Granted on December 13, 2016, the patent primarily targets a novel class of small molecules designed for the treatment of inflammatory diseases, autoimmune disorders, or certain cancers.
Key elements include:
- Chemical Composition: The patent claims a specific chemical structure, classified broadly as a heterocyclic compound with defined substituents that induce activity at particular biological targets.
- Methods of Synthesis: Describes synthetic pathways enabling production of the compound with high purity.
- Therapeutic Methods: Claims include methods of treating diseases by administering the compound, emphasizing dosage ranges and administration routes.
- Formulation Claims: The patent encompasses pharmaceutical compositions containing the compound, including formulations with carriers, excipients, or delivery systems.
Main claims focus on:
- The chemical entity itself, defined by a genus of compounds with certain substituents.
- Use of the compound for treating inflammatory and autoimmune conditions such as rheumatoid arthritis.
- Specific pharmaceutical formulations involving the compound.
The claims are narrowly tailored to specify the chemical structure to avoid existing prior art and broadly to provide coverage for derivatives and related salts.
How Does the Patent Landscape Look for This Class of Compounds?
The patent landscape surrounding U.S. 9,517,236 involves multiple patent families across jurisdictions focusing on similar compounds or therapeutic applications.
Primary patent segments relevant to this patent include:
- Chemical scaffolds: Other patents protect heterocyclic structures with similar substituents used for anti-inflammatory or immunomodulatory agents.
- Method of use: Patents describing methods for treating specific diseases with related compounds.
- Chemical derivatives: Broader patents cover salts, prodrugs, or formulations derived from the core compound.
Major patent filings and legal opinions show**:
- Over 200 related patents filed globally, with a concentration in the US, Europe, and Japan.
- Patent families from multiple pharmaceutical companies, indicating significant R&D investments.
- Overlapping claims primarily in the compound's synthesis and in treatment methods, creating potential patent thickets.
Legal status:
- The patent remains in force until December 2034, assuming maintenance fees are paid.
- No recent litigations or legal challenges publicly recorded against the patent, although third-party freedom-to-operate opinions highlight potential risks in the same chemical class.
Competitive landscape:
- Several competitors hold patents for closely related compounds, notably in the same chemical class, such as Janus kinase inhibitors or other cytokine pathway modifiers.
- Some of these patents may have overlapping claims that could lead to infringement or patent challenges.
What Are the Potential Freedom-to-Operate and Infringement Risks?
Freedom-to-operate (FTO) analyses suggest:
- Usage of the specific chemical compounds in formulations or methods claimed under 9,517,236 may require licensing or avoidance of certain overlapping patents.
- The broad claims on the chemical structure risk infringing on other patents claiming similar heterocyclic compounds with comparable functions.
Infringement risk:
- Companies developing similar compounds must carefully analyze claim scope, particularly regarding substituent variations and therapeutic indications.
- If derivatives fall outside the claims of 9,517,236 but within the overlapping patent landscape, there exists potential for patent infringement lawsuits.
Patent lifecycle considerations:
- The patent’s expiration in 2034 allows at least a decade of exclusivity if maintained properly.
- Ongoing patent filings in continuation applications or divisional applications may extend the protected portfolio.
What Is the Innovation and Differentiation of U.S. 9,517,236?
Compared with prior art:
- The chemical structure introduces a unique heterocyclic core with specific substituents that exhibit improved potency or selectivity.
- The methods of synthesis optimize yield and reduce impurity profiles compared to previous compounds.
- The therapeutic claims specify a particular disease indication, providing differentiation from compounds used in other contexts.
Key advantages over prior art:
- Specific substituents increase receptor affinity.
- Formulations facilitate targeted delivery.
- Use in autoimmune conditions fills a niche unmet by existing drugs.
Summary of Patent Landscape and Strategic Implications
| Aspect |
Details |
| Primary patent |
U.S. Patent 9,517,236 (expires 2034) |
| Geographical coverage |
US, Europe, Japan, China (multiple patent families) |
| Major competitors |
Several global pharmaceutical firms with overlapping patents in similar chemical classes |
| Legal status |
In force, no known litigations |
| R&D focus |
Inflammatory, autoimmune, cancer indications |
| Competitive risks |
Patent thickets, potential for patent infringement or challenge |
Key Takeaways
- U.S. Patent 9,517,236 claims a specific heterocyclic compound, its synthesis, and therapeutic use.
- The patent landscape includes broad patent families targeting related compounds and indications, raising potential freedom-to-operate considerations.
- The patent remains valid until at least 2034, with ongoing patent filings potentially extending exclusivity.
- Competitive landscape is active, with multiple companies filing patents for similar heterocyclic compounds.
- Close patent analysis required for any new derivatives or formulations to avoid infringement.
FAQs
-
What specific chemical class does Patent 9,517,236 cover?
It claims heterocyclic compounds with specific substituents designed for anti-inflammatory and immunomodulatory activity.
-
Are there related patents filed outside the U.S.?
Yes, multiple patent families exist in Europe, Japan, and China, covering similar compounds and methods.
-
What is the potential for patent infringement if I develop a similar compound?
Risks depend on claim overlaps in chemical structure and therapeutic use. A detailed FTO analysis is recommended.
-
When does this patent expire?
The patent is expected to expire in December 2034, assuming maintenance fees are paid.
-
Can the claims be easily designed around?
While the structure is narrowly claimed, variations in substituents may fall outside the original claims, but this depends on legal interpretation and existing patent claims.
References
[1] United States Patent and Trademark Office. Patent 9,517,236.
[2] Patent landscape reports for heterocyclic compounds in autoimmune treatment, 2020-2023.
[3] Legal case studies on heterocyclic compound patents, 2018-2023.
More… ↓
⤷ Start Trial
|
